Share on StockTwits

Cantor Fitzgerald reduced their target price on shares of Ventrus Biosciences (NASDAQ:VTUS) from $6.00 to $2.50 in a research note issued on Thursday, StockRatingsNetwork reports. Cantor Fitzgerald’s price objective points to a potential upside of 62.34% from the company’s current price.

Separately, analysts at William Blair downgraded shares of Ventrus Biosciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday.

Ventrus Biosciences (NASDAQ:VTUS) opened at 1.62 on Thursday. Ventrus Biosciences has a 52 week low of $1.47 and a 52 week high of $4.69. The stock has a 50-day moving average of $3.85 and a 200-day moving average of $3.09. The company’s market cap is $33.8 million.

Ventrus Biosciences, Inc (NASDAQ:VTUS) is a specialty pharmaceutical company focused on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.